Real-world Comparative Effectiveness of Rivaroxaban Versus VKA "RIVA-F"

Completed

Phase N/A Results N/A

Trial Description

To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting

Conditions

Interventions

  • Rivaroxaban (Xarelto, BAY59-7939) Drug
    Intervention Desc: As prescribed by treating physicians
    ARM 1: Kind: Experimental
    Label: Rivaroxaban
    Description: NVAF patients who were initiated on rivaroxaban for stroke prevention
  • VKA (Vitamin K antagonist) Drug
    Intervention Desc: As prescribed by treating physicians
    ARM 1: Kind: Experimental
    Label: VKA (Vitamin K antagonist)
    Description: NVAF patients who were initiated on VKA for stroke prevention

Trial Design

  • Observation: Cohort
  • Perspective: Retrospective
  • Sampling: Non-Probability Sample

Trial Population

Patients with non-valvular atrial fibrillation (NVAF)

Outcomes

Type Measure Time Frame Safety Issue
Primary Incidence of Hospitalization Events (composite endpoint) Within 2 years of starting treatment Yes

Sponsors